Appili Therapeutics Inc. reported a net and comprehensive loss of CAD 1 million, or CAD 0.01 per share, for the third quarter (Q3) of fiscal year 2026, ended December 31, 2025. The loss increased by 100% compared to the same period in the previous year, mainly due to a CAD 2.6 million reduction in government assistance, partially offset by a CAD 1.2 million decrease in research and development expenses, a CAD 0.2 million decrease in general and administrative expenses, and a CAD 0.7 million increase in foreign exchange gains. The company’s cash balance as of December 31, 2025, was CAD 0.2 million, compared to CAD 1.2 million as of March 31, 2025. During the quarter, Appili Therapeutics Inc. highlighted US$82 million in pending proposals across multiple infectious disease programs and a US$40 million funding award from NIAID supporting the development of VXV-01 through Phase 1. The company also reported increased U.S. market adoption of LIKMEZ (ATI-1501). Appili continues to leverage government funding, having secured over US$75 million since inception, to advance its infectious disease and biodefense pipeline, including manufacturing, preclinical studies, regulatory activities, and clinical trial preparation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Appili Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9654246-en) on February 12, 2026, and is solely responsible for the information contained therein.